Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review

Molecular Biology Reports

Volumn 42, Issue 11, 2015, Pages 1515-1531

  Singh, Prabhat ^a   Tomar, Raghuvir Singh ^a   Rath, Srikanta Kumar ^b  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHOPAL   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Cancer; Chemoprevention; Flavones; Histone deacetylase inhibitors; Histone deacetylases

Indexed keywords

ABEXINOSTAT; ANTINEOPLASTIC AGENT; APIGENIN; APIGENIN DERIVATIVE; BAFILOMYCIN A1; BELINOSTAT; BUTYRIC ACID; CHLOROQUINE; CHRYSIN; CYCLOPEPTIDE; DEPSIPEPTIDE; ENTINOSTAT; FLAVONE DERIVATIVE; FLAVONOID; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LUTEOLIN; MOCETINOSTAT; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; POLYPHENOL DERIVATIVE; PROTOAPIGENONE; RESMINOSTAT; ROMIDEPSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CARCINOGENESIS; CELL DIVISION; CELL INVASION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIET; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; EPIGENETICS; FATIGUE; GENE MUTATION; HUMAN; NAUSEA; NEOPLASM; NONHUMAN; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; GENETIC EPIGENESIS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; FLAVONES; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 84946484316     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-015-3881-y     Document Type: Review

References (149)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166
2. Tano K, Akimitsu N (2012) Long non-coding RNAs in cancer progression. Front Genet 3:219. doi:10.3389/fgene.2012.00219
3. Mandal P, Verma N, Chauhan S, Tomar RS (2013) Unexpected histone H3 tail clipping activity of Glutamate dehydrogenase. J Biol Chem. doi:10.1074/jbc.M113.462531
4. Santos-Rosa H, Kirmizis A, Nelson C, Bartke T, Saksouk N, Cote J, Kouzarides T (2009) Histone H3 tail clipping regulates gene expression. Nat Struct Mol Biol 16(1):17–22. doi:10.1038/nsmb.1534
5. Chervona Y, Costa M (2012) Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res 2(5):589
6. Arts IC, Hollman PC (2005) Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 81(1 Suppl):317S–325S
7. Messing E, Gee JR, Saltzstein DR, Kim K, diSant’Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H (2012) A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila) 5(4):621–630. doi:10.1158/1940-6207.CAPR-11-0455
8. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2(4):659–668
9. Srivastava N, Chauhan AS, Sharma B (2012) Isolation and characterization of some phytochemicals from Indian traditional plants. Biotechnol Res Int 2012:549850. doi:10.1155/2012/549850
10. Allfrey VG, Littau VC, Mirsky AE (1964) Methods for the purification of thymus nuclei and their application to studies of nuclear protein synthesis. J Cell Biol 21:213–231
11. Taunton J, Hassig CA, Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272(5260):408–411
12. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338(1):17–31. doi:10.1016/j.jmb.2004.02.006
13. Yang XJ, Seto E (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37):5310–5318. doi:10.1038/sj.onc.1210599
14. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN (2009) Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA 106(19):7751–7755. doi:10.1073/pnas.0903139106
15. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370(Pt 3):737–749. doi:10.1042/BJ20021321
16. Longworth MS, Laimins LA (2006) Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene 25(32):4495–4500. doi:10.1038/sj.onc.1209473
17. Waltregny D, Glenisson W, Tran SL, North BJ, Verdin E, Colige A, Castronovo V (2005) Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J 19(8):966–968. doi:10.1096/fj.04-2303fje
18. Reichert N, Choukrallah MA, Matthias P (2012) Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 69(13):2173–2187. doi:10.1007/s00018-012-0921-9
19. Segre CV, Chiocca S (2011) Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2011:690848. doi:10.1155/2011/690848
20. Karagianni P, Wong J (2007) HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 26(37):5439–5449. doi:10.1038/sj.onc.1210612
21. Nicolas E, Ait-Si-Ali S, Trouche D (2001) The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein. Nucleic Acids Res 29(15):3131–3136
22. Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G, Giguere V (2010) An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. Mol Endocrinol 24(7):1349–1358. doi:10.1210/me.2009-0441
23. Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19(5):286–293. doi:10.1016/S0168-9525(03)00073-8
24. Yang XJ, Gregoire S (2005) Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 25(8):2873–2884. doi:10.1128/MCB.25.8.2873-2884.2005
25. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E (2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276(38):35826–35835. doi:10.1074/jbc.M104935200
26. Berger I, Bieniossek C, Schaffitzel C, Hassler M, Santelli E, Richmond TJ (2003) Direct interaction of Ca2+/calmodulin inhibits histone deacetylase 5 repressor core binding to myocyte enhancer factor 2. J Biol Chem 278(20):17625–17635. doi:10.1074/jbc.M301646200
27. Lu J, McKinsey TA, Nicol RL, Olson EN (2000) Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA 97(8):4070–4075. doi:10.1073/pnas.080064097
28. Kato H, Tamamizu-Kato S, Shibasaki F (2004) Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279(40):41966–41974. doi:10.1074/jbc.M406320200
29. Lemercier C, Brocard MP, Puvion-Dutilleul F, Kao HY, Albagli O, Khochbin S (2002) Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 277(24):22045–22052. doi:10.1074/jbc.M201736200
30. Watamoto K, Towatari M, Ozawa Y, Miyata Y, Okamoto M, Abe A, Naoe T, Saito H (2003) Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene 22(57):9176–9184. doi:10.1038/sj.onc.1206902
31. Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277(28):25748–25755. doi:10.1074/jbc.M111871200
32. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, Garcia-Wilson E, Perkins ND, Hay RT (2003) P300 transcriptional repression is mediated by SUMO modification. Mol Cell 11(4):1043–1054
33. Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O, Lee HS, Eng F, Bertos NR, Pelletier N, Mader S, Han VK, Yang XJ, White JH (2003) Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell 11(1):139–150
34. Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S (2004) Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279(9):7685–7691. doi:10.1074/jbc.M310997200
35. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417–435. doi:10.1146/annurev.biochem.73.011303.073651
36. Saunders LR, Verdin E (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26(37):5489–5504. doi:10.1038/sj.onc.1210616
37. Liu H, Hu Q, D’Ercole AJ, Ye P (2009) Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells. Glia 57(1):1–12. doi:10.1002/glia.20729
38. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM (2009) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10(1):92–100. doi:10.1038/ni.1673
39. Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Mol Oncol 6(6):579–589. doi:10.1016/j.molonc.2012.07.003
40. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265(28):17174–17179
41. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31–39. doi:10.1182/blood-2006-06-025999
42. Bi G, Jiang G (2006) The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 3(4):285–290
43. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13(1):1–13
44. Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90(1):85–94. doi:10.1038/icb.2011.100
45. Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32(3):157–165. doi:10.1016/j.ctrv.2005.12.006
46. Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3(9):2751–2767
47. Beecher GR (2003) Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 133(10):3248S–3254S
48. Senderowicz AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17(3):313–320
49. Liang Y-C, Huang Y-T, Tsai S-H, Lin-Shiau S-Y, Chen C-F, Lin J-K (1999) Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20(10):1945–1952
50. Romanova D, Vachalkova A, Cipak L, Ovesna Z, Rauko P (2000) Study of antioxidant effect of apigenin, luteolin and quercetin by DNA protective method. Neoplasma 48(2):104–107
51. Singh P, Mishra P, Verma AK, Srivastava P, Sharma S, Rath SK (2011) The Protective effect of apigenin against lithocholic acid-induced oxidative stress and toxicity in hepatic cell lines. Atla-Altern Lab Anim 39(1):96
52. Yang CS, Landau JM, Huang M-T, Newmark HL (2001) Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21(1):381–406
53. Middleton E, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52(4):673–751
54. Martini ND, Katerere DRP, Eloff JN (2004) Biological activity of five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae). J Ethnopharmacol 93(2–3):207–212. doi:10.1016/j.jep.2004.02.030
55. Fang F, Li J-M, Pan Q-H, Huang W-D (2007) Determination of red wine flavonoids by HPLC and effect of aging. Food Chem 101(1):428–433
56. Shimada H, Miura K, Imamura Y (2006) Characteristics and inhibition by flavonoids of 20alpha-hydroxysteroid dehydrogenase activity in mouse tissues. Life Sci 78(25):2931–2936. doi:10.1016/j.lfs.2005.11.022
57. Engelmann C, Blot E, Panis Y, Bauer S, Trochon V, Nagy HJ, Lu H, Soria C (2002) Apigenin–strong cytostatic and anti-angiogenic action in vitro contrasted by lack of efficacy in vivo. Phytomedicine 9(6):489–495. doi:10.1078/09447110260573100
58. Kachadourian R, Day BJ (2006) Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic Biol Med 41(1):65–76. doi:10.1016/j.freeradbiomed.2006.03.002
59. Cárdenas M, Marder M, Blank VC, Roguin LP (2006) Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg Med Chem 14(9):2966–2971
60. Pandey M, Kaur P, Shukla S, Abbas A, Fu P, Gupta S (2012) Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol Carcinog 51(12):952–962. doi:10.1002/mc.20866
61. Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, Yu XD (2011) Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer 10:104. doi:10.1186/1476-4598-10-104
62. Tsai SC, Seto E (2002) Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem 277(35):31826–31833. doi:10.1074/jbc.M204149200
63. Singh N, Ravichandran S, Norton DD, Fugmann SD, Moaddel R (2013) Synthesis and characterization of a SIRT6 open tubular column: predicting deacetylation activity using frontal chromatography. Anal Biochem 436(2):78–83. doi:10.1016/j.ab.2013.01.018
64. Pal-Bhadra M, Ramaiah MJ, Reddy TL, Krishnan A, Pushpavalli SN, Babu KS, Tiwari AK, Rao JM, Yadav JS, Bhadra U (2012) Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells. BMC Cancer 12:180. doi:10.1186/1471-2407-12-180
65. Sun LP, Chen AL, Hung HC, Chien YH, Huang JS, Huang CY, Chen YW, Chen CN (2012) Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis. J Agric Food Chem 60(47):11748–11758. doi:10.1021/jf303261r
66. Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, Gaben AM, Bracke M, Awad S, John A, Kamalboor HA, Al Sultan MA, Arafat K, Gespach C, Petroianu G (2011) Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol 651(1–3):18–25. doi:10.1016/j.ejphar.2010.10.063
67. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99(18):11700–11705. doi:10.1073/pnas.182372299
68. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102(3):673–678. doi:10.1073/pnas.0408732102
69. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98(19):10833–10838. doi:10.1073/pnas.191208598
70. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K (1976) A new antifungal antibiotic, trichostatin. J Antibiot 29(1):1–6
71. Miyoshi N, Naniwa K, Yamada T, Osawa T, Nakamura Y (2007) Dietary flavonoid apigenin is a potential inducer of intracellular oxidative stress: the role in the interruptive apoptotic signal. Arch Biochem Biophys 466(2):274–282. doi:10.1016/j.abb.2007.07.026
72. Singh P, Mishra SK, Noel S, Sharma S, Rath SK (2012) Acute exposure of apigenin induces hepatotoxicity in Swiss mice. PLoS One 7(2):e31964. doi:10.1371/journal.pone.0031964
73. Chan LP, Chou TH, Ding HY, Chen PR, Chiang FY, Kuo PL, Liang CH (2012) Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim Biophys Acta 1820(7):1081–1091. doi:10.1016/j.bbagen.2012.04.013
74. Laberge RM, Karwatsky J, Lincoln MC, Leimanis ML, Georges E (2007) Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochem Pharmacol 73(11):1727–1737. doi:10.1016/j.bcp.2007.02.005
75. Abate A, Yang G, Wong RJ, Schroder H, Stevenson DK, Dennery PA (2005) Apigenin decreases hemin-mediated heme oxygenase-1 induction. Free Radic Biol Med 39(6):711–718. doi:10.1016/j.freeradbiomed.2005.01.020
76. Shin GC, Kim C, Lee JM, Cho WS, Lee SG, Jeong M, Cho J, Lee K (2009) Apigenin-induced apoptosis is mediated by reactive oxygen species and activation of ERK1/2 in rheumatoid fibroblast-like synoviocytes. Chem Biol Interact 182(1):29–36. doi:10.1016/j.cbi.2009.07.016
77. Chen WY, Hsieh YA, Tsai CI, Kang YF, Chang FR, Wu YC, Wu CC (2011) Protoapigenone, a natural derivative of apigenin, induces mitogen-activated protein kinase-dependent apoptosis in human breast cancer cells associated with induction of oxidative stress and inhibition of glutathione S-transferase pi. Invest New Drugs 29(6):1347–1359. doi:10.1007/s10637-010-9497-0
78. Goto H, Yanagimachi M, Goto S, Takeuchi M, Kato H, Yokosuka T, Kajiwara R, Yokota S (2012) Methylated chrysin reduced cell proliferation, but antagonized cytotoxicity of other anticancer drugs in acute lymphoblastic leukemia. Anticancer Drugs 23(4):417–425. doi:10.1097/CAD.0b013e32834fb731
79. Ju W, Wang X, Shi H, Chen W, Belinsky SA, Lin Y (2007) A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 71(5):1381–1388. doi:10.1124/mol.106.032185
80. Rao PS, Satelli A, Moridani M, Jenkins M, Rao US (2012) Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. Int J Cancer 130(11):2703–2714. doi:10.1002/ijc.26308
81. Chen Q, Liu S, Chen J, Zhang Q, Lin S, Chen Z, Jiang J (2012) Luteolin induces mitochondria-dependent apoptosis in human lung adenocarcinoma cell. Nat Prod Commun 7(1):29–32
82. Choi AY, Choi JH, Yoon H, Hwang KY, Noh MH, Choe W, Yoon KS, Ha J, Yeo EJ, Kang I (2011) Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells. Eur J Pharmacol 668(1–2):115–126. doi:10.1016/j.ejphar.2011.06.047
83. Park SH, Park HS, Lee JH, Chi GY, Kim GY, Moon SK, Chang YC, Hyun JW, Kim WJ, Choi YH (2013) Induction of endoplasmic reticulum stress-mediated apoptosis and non-canonical autophagy by luteolin in NCI-H460 lung carcinoma cells. Food Chem Toxicol 56:100–109. doi:10.1016/j.fct.2013.02.022
84. Michels G, Watjen W, Niering P, Steffan B, Thi QH, Chovolou Y, Kampkotter A, Bast A, Proksch P, Kahl R (2005) Pro-apoptotic effects of the flavonoid luteolin in rat H4IIE cells. Toxicology 206(3):337–348. doi:10.1016/j.tox.2004.07.022
85. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, Aladjem MI, Pommier Y (2010) Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 70(11):4470–4480. doi:10.1158/0008-5472.CAN-09-3028
86. Petruccelli LA, Dupere-Richer D, Pettersson F, Retrouvey H, Skoulikas S, Miller WH Jr (2011) Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 6(6):e20987. doi:10.1371/journal.pone.0020987
87. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM (2009) PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 15(10):3354–3365. doi:10.1158/1078-0432.CCR-08-2365
88. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C (2009) Histone deacetylase inhibitors and genomic instability. Cancer Lett 274(2):169–176. doi:10.1016/j.canlet.2008.06.005
89. Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421(6922):499–506. doi:10.1038/nature01368
90. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ (2007) HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 104(49):19482–19487. doi:10.1073/pnas.0707828104
91. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M (2007) Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 168(1):115–124. doi:10.1667/RR0811.1
92. Lu HF, Chie YJ, Yang MS, Lu KW, Fu JJ, Yang JS, Chen HY, Hsia TC, Ma CY, Ip SW, Chung JG (2011) Apigenin induces apoptosis in human lung cancer H460 cells through caspase- and mitochondria-dependent pathways. Hum Exp Toxicol 30(8):1053–1061. doi:10.1177/0960327110386258
93. Arango D, Parihar A, Villamena FA, Wang L, Freitas MA, Grotewold E, Doseff AI (2012) Apigenin induces DNA damage through the PKCdelta-dependent activation of ATM and H2AX causing down-regulation of genes involved in cell cycle control and DNA repair. Biochem Pharmacol 84(12):1571–1580. doi:10.1016/j.bcp.2012.09.005
94. Leung HW, Wu CH, Lin CH, Lee HZ (2005) Luteolin induced DNA damage leading to human lung squamous carcinoma CH27 cell apoptosis. Eur J Pharmacol 508(1–3):77–83. doi:10.1016/j.ejphar.2004.12.032
95. McVean M, Weinberg WC, Pelling JC (2002) A p21(waf1)-independent pathway for inhibitory phosphorylation of cyclin-dependent kinase p34(cdc2) and concomitant G(2)/M arrest by the chemopreventive flavonoid apigenin. Mol Carcinog 33(1):36–43
96. Lepley DM, Li B, Birt DF, Pelling JC (1996) The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis 17(11):2367–2375
97. Yin F, Giuliano AE, Law RE, Van Herle AJ (2001) Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 21(1A):413–420
98. Sato F, Matsukawa Y, Matsumoto K, Nishino H, Sakai T (1994) Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells. Biochem Biophys Res Commun 204(2):578–584. doi:10.1006/bbrc.1994.2498
99. Takagaki N, Sowa Y, Oki T, Nakanishi R, Yogosawa S, Sakai T (2005) Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. Int J Oncol 26(1):185–189
100. Trochon V, Blot E, Cymbalista F, Engelmann C, Tang RP, Thomaidis A, Vasse M, Soria J, Lu H, Soria C (2000) Apigenin inhibits endothelial-cell proliferation in G(2)/M phase whereas it stimulates smooth-muscle cells by inhibiting P21 and P27 expression. Int J Cancer 85(5):691–696
101. Seo HS, Choi HS, Kim SR, Choi YK, Woo SM, Shin I, Woo JK, Park SY, Shin YC, Ko SG (2012) Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFkappaB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem 366(1–2):319–334. doi:10.1007/s11010-012-1310-2
102. Weng MS, Ho YS, Lin JK (2005) Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: involvement of p38 mitogen-activated protein kinase. Biochem Pharmacol 69(12):1815–1827. doi:10.1016/j.bcp.2005.03.011
103. Pilatova M, Stupakova V, Varinska L, Sarissky M, Mirossay L, Mirossay A, Gal P, Kraus V, Dianiskova K, Mojzis J (2010) Effect of selected flavones on cancer and endothelial cells. Gen Physiol Biophys 29(2):134–143
104. Ong CS, Zhou J, Ong CN, Shen HM (2010) Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3beta-Cyclin D1 pathway. Cancer Lett 298(2):167–175. doi:10.1016/j.canlet.2010.07.001
105. Verschooten L, Barrette K, Van Kelst S, Rubio Romero N, Proby C, De Vos R, Agostinis P, Garmyn M (2012) Autophagy inhibitor chloroquine enhanced the cell death inducing effect of the flavonoid luteolin in metastatic squamous cell carcinoma cells. PLoS One 7(10):e48264. doi:10.1371/journal.pone.0048264
106. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L, Fusco A (2010) Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29(1):105–116. doi:10.1038/onc.2009.306
107. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11(1):77–84. doi:10.1038/nm1161
108. Rosato RR, Almenara JA, Dai Y, Grant S (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2(12):1273–1284
109. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102(44):16090–16095. doi:10.1073/pnas.0505585102
110. Seo YJ, Kim BS, Chun SY, Park YK, Kang KS, Kwon TG (2011) Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1. J Korean Med Sci 26(11):1489–1494. doi:10.3346/jkms.2011.26.11.1489
111. Zhao X, Shu G, Chen L, Mi X, Mei Z, Deng X (2012) A flavonoid component from Docynia delavayi (Franch.) Schneid represses transplanted H22 hepatoma growth and exhibits low toxic effect on tumor-bearing mice. Food Chem Toxicol 50(9):3166–3173. doi:10.1016/j.fct.2012.05.039
112. Cai X, Lu W, Ye T, Lu M, Wang J, Huo J, Qian S, Wang X, Cao P (2012) The molecular mechanism of luteolin-induced apoptosis is potentially related to inhibition of angiogenesis in human pancreatic carcinoma cells. Oncol Rep 28(4):1353–1361. doi:10.3892/or.2012.1914
113. Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, Chen G, Zhang Z, Luo J, Shi X (2012) Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One 7(12):e52279. doi:10.1371/journal.pone.0052279
114. Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, Wu GJ, Hsieh SC, Hsiao PW (2009) Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 15(17):5435–5444. doi:10.1158/1078-0432.CCR-09-0298
115. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8(9):741–752. doi:10.1038/nrm2239
116. Hippert MM, O’Toole PS, Thorburn A (2006) Autophagy in cancer: good, bad, or both? Cancer Res 66(19):9349–9351. doi:10.1158/0008-5472.CAN-06-1597
117. Rikiishi H (2011) Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011:830260. doi:10.1155/2011/830260
118. Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101(52):18030–18035. doi:10.1073/pnas.0408345102
119. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Investig 117(2):326–336. doi:10.1172/JCI28833
120. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110(1):313–322. doi:10.1182/blood-2006-10-050260
121. Cao X, Liu B, Cao W, Zhang W, Zhang F, Zhao H, Meng R, Zhang L, Niu R, Hao X, Zhang B (2013) Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells. Chin J Cancer Res 25(2):212–222. doi:10.3978/j.issn.1000-9604.2013.04.01
122. Mohan N, Banik NL, Ray SK (2011) Combination of N-(4-hydroxyphenyl) retinamide and apigenin suppressed starvation-induced autophagy and promoted apoptosis in malignant neuroblastoma cells. Neurosci Lett 502(1):24–29. doi:10.1016/j.neulet.2011.07.016
123. Tong X, Smith KA, Pelling JC (2012) Apigenin, a chemopreventive bioflavonoid, induces AMP-activated protein kinase activation in human keratinocytes. Mol Carcinog 51(3):268–279. doi:10.1002/mc.20793
124. Huang HC, Syu KY, Lin JK (2010) Chemical composition of Solanum nigrum linn extract and induction of autophagy by leaf water extract and its major flavonoids in AU565 breast cancer cells. J Agric Food Chem 58(15):8699–8708. doi:10.1021/jf101003v
125. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, Bae MK, Kim KW (2007) Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 17(3):647–651
126. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J (2006) Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26(6):2019–2028. doi:10.1128/MCB.26.6.2019-2028.2006
127. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH (2005) Apigenin inhibits VEGF and HIF-1 expression via PI3 K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19(3):342–353. doi:10.1096/fj.04-2175com
128. Liu LZ, Fang J, Zhou Q, Hu X, Shi X, Jiang BH (2005) Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol 68(3):635–643. doi:10.1124/mol.105.011254
129. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X, Jiang BH (2007) Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28(4):858–864. doi:10.1093/carcin/bgl205
130. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C (2005) Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer 117(5):764–774. doi:10.1002/ijc.21268
131. Osada M, Imaoka S, Funae Y (2004) Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett 575(1–3):59–63. doi:10.1016/j.febslet.2004.08.036
132. Anso E, Zuazo A, Irigoyen M, Urdaci MC, Rouzaut A, Martinez-Irujo JJ (2010) Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem Pharmacol 79(11):1600–1609. doi:10.1016/j.bcp.2010.02.004
133. Mafuvadze B, Benakanakere I, Hyder SM (2010) Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells. Menopause 17(5):1055–1063. doi:10.1097/gme.0b013e3181dd052f
134. Kim MH (2003) Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 89(3):529–538. doi:10.1002/jcb.10543
135. Shukla S, MacLennan GT, Fu P, Gupta S (2012) Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model. Pharm Res 29(6):1506–1517. doi:10.1007/s11095-011-0625-0
136. Lamy S, Bedard V, Labbe D, Sartelet H, Barthomeuf C, Gingras D, Beliveau R (2008) The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through inhibition of PDGFR-beta phosphorylation. Cancer Prev Res (Phila) 1(6):452–459. doi:10.1158/1940-6207.CAPR-08-0072
137. Mirzoeva S, Franzen CA, Pelling JC (2013) Apigenin inhibits TGF-beta-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism. Mol Carcinog. doi:10.1002/mc.22005
138. Schindler R, Mentlein R (2006) Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J Nutr 136(6):1477–1482
139. Erdogan A, Most AK, Wienecke B, Fehsecke A, Leckband C, Voss R, Grebe MT, Tillmanns H, Schaefer CA, Kuhlmann CR (2007) Apigenin-induced nitric oxide production involves calcium-activated potassium channels and is responsible for antiangiogenic effects. J Thromb Haemost 5(8):1774–1781. doi:10.1111/j.1538-7836.2007.02615.x
140. Nangia-Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, Piechocki MP, Funasaka T, Raz A (2007) Inhibition of breast tumor growth and angiogenesis by a medicinal herb: ocimum gratissimum. Int J Cancer 121(4):884–894. doi:10.1002/ijc.22733
141. Ahn MR, Kunimasa K, Kumazawa S, Nakayama T, Kaji K, Uto Y, Hori H, Nagasawa H, Ohta T (2009) Correlation between antiangiogenic activity and antioxidant activity of various components from propolis. Mol Nutr Food Res 53(5):643–651. doi:10.1002/mnfr.200800021
142. Lin CM, Shyu KG, Wang BW, Chang H, Chen YH, Chiu JH (2010) Chrysin suppresses IL-6-induced angiogenesis via down-regulation of JAK1/STAT3 and VEGF: an in vitro and in ovo approach. J Agric Food Chem 58(11):7082–7087. doi:10.1021/jf100421w
143. Lin CM, Chang H, Li SY, Wu IH, Chiu JH (2006) Chrysin inhibits lipopolysaccharide-induced angiogenesis via down-regulation of VEGF/VEGFR-2(KDR) and IL-6/IL-6R pathways. Planta Med 72(8):708–714. doi:10.1055/s-2006-931602
144. Fu B, Xue J, Li Z, Shi X, Jiang BH, Fang J (2007) Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther 6(1):220–226. doi:10.1158/1535-7163.MCT-06-0526
145. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C, Fotsis T (2004) Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 64(21):7936–7946. doi:10.1158/0008-5472.CAN-03-3104
146. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer L (1997) Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57(14):2916–2921
147. Lamy S, Akla N, Ouanouki A, Lord-Dufour S, Beliveau R (2012) Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Exp Cell Res 318(13):1586–1596. doi:10.1016/j.yexcr.2012.04.004
148. Zhu M, Chen D, Li D, Ding H, Zhang T, Xu T, Zhang Y (2013) Luteolin inhibits angiotensin II-induced human umbilical vein endothelial cell proliferation and migration through downregulation of Src and Akt phosphorylation. Circ J 77(3):772–779
149. Myzak MC, Dashwood RH (2006) Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets 7(4):443–452